Published 4 days ago

Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025

Summary

Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen investor concerns that the company is losing its edge in the competitive obesity market to rival Eli Lilly. The Danish company said it expects sales growth this year between 16% and 24%, a weaker forecast than it made a year ago, as demand softens for its obesity drug Wegovy and diabetes drug Ozempic, which contain the same active ingredient.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year